Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

BACKGROUND: Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors would correlate with clinical responses. New ultr...

Descripción completa

Detalles Bibliográficos
Autores principales: Keegan, Alissa, Ricciuti, Biagio, Garden, Padric, Cohen, Limor, Nishihara, Reiko, Adeni, Anika, Paweletz, Cloud, Supplee, Julianna, Jänne, Pasi A, Severgnini, Mariano, Awad, Mark M, Walt, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537334/
https://www.ncbi.nlm.nih.gov/pubmed/33020238
http://dx.doi.org/10.1136/jitc-2020-000678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537334/
https://www.ncbi.nlm.nih.gov/pubmed/33020238
http://dx.doi.org/10.1136/jitc-2020-000678

Ejemplares similares